Drug Profile
Research programme: Alzheimer's disease therapeutics - Senexis
Alternative Names: SEN1176; SEN1500; SEN1576; SEN304; SEN606Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Senexis
- Class Peptides; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 22 Feb 2011 Preclinical development is ongoing in United Kingdom
- 13 Nov 2010 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)